Your browser doesn't support javascript.
loading
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
Zou, Jianxuan; Chen, Dan; Zong, Yunhui; Ye, Sisi; Tang, Jinle; Meng, Huimin; An, Gangli; Zhang, Xingding; Yang, Lin.
Afiliación
  • Zou J; The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
  • Chen D; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Zong Y; The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
  • Ye S; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Tang J; Suzhou Cancer Immunotherapy and Diagnosis Engineering Center, Suzhou, China.
  • Meng H; Suzhou Cancer Immunotherapy and Diagnosis Engineering Center, Suzhou, China.
  • An G; The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
  • Zhang X; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Yang L; The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
Cancer Sci ; 106(5): 512-21, 2015 May.
Article en En | MEDLINE | ID: mdl-25664501
ABSTRACT
Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab-CD3), showed great performance in clinical treatment. We have successfully developed a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI-8226 cells than that of separate aCD3-ScFv-hIgFc and aCD138-ScFv-hIgFc, or the isotype mAb in vitro or in vivo.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Anticuerpos de Cadena Única / Inmunoterapia / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Sci Año: 2015 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Anticuerpos de Cadena Única / Inmunoterapia / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Sci Año: 2015 Tipo del documento: Article País de afiliación: China